Skip to main content
NCBI home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
. 2012 Apr 12;2(1):75–80. doi: 10.1016/S0973-6883(12)60084-X

HBsAg Quantification in Clinical Practice

Avnish K Seth 1,*
PMCID: PMC3940596  PMID: 25755408

Abstract

Several standardized commercial assays for quantification of hepatitis B surface antigen (qHBsAg) are now available. Studies on HBsAg kinetics from Asia and Europe have demonstrated that HBsAg levels are highest during the immune-tolerant phase, become lower during immune-clearance phase and are the lowest in hepatitis B ‘e’ antigen (HBeAg)-negative inactive low-replicative phase with a rise during HBeAg-negative chronic hepatitis B (CHB). Combined use of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) and HBsAg levels may help in differentiating true inactive carrier state from HBeAg-negative CHB. Several retrospective studies have demonstrated a role for decline in HBsAg level for predicting response and nonresponse to therapy. In HBeAg-positive patients treated with pegylated-interferon (PEG-IFN), a lack of decline of qHBsAg at week 12 predicts nonresponders while a decline of qHBsAg at week 24 predicts responders to PEG-IFN. In HBeAg-negative patients, if at week 12, there is no decline in qHBsAg and the HBV-DNA decline is < 2 log, the patient is unlikely to respond, then stopping of PEG-IFN should be considered. With nucleos(t)ide analogs, the decline in HBsAg is lower than that with PEG-IFN and more marked in patients with HBeAg-positive chronic hepatitis, with elevated alanine aminotransaminase (ALT), thus suggesting that active immune response against HBV is required to lower HBsAg. In patients with HBeAg-negative chronic hepatitis, fall in HBsAg may help in developing stopping rules to reduce the need for lifelong therapy. Information provided by HBsAg is complementary to HBV-DNA and cannot replace the same. Prospective studies on HBsAg kinetics from all regions of the world are required to define optimum time of testing and cutoff levels before stopping rules can be recommended.

Keywords: Chronic hepatitis B, HBsAg quantification, hepatitis B virus, nucleos(t)ide, pegylated-interferon

Abbreviations: ALT, alanine amino transaminase; cccDNA, covalently closed circular deoxyribonucleic acid; CHB, chronic hepatitis B; HBeAg, hepatitis B ‘e’ antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NPV, negative-predictive value; PEG-IFN, pegylated-interferon; PPV, positive-predictive value; qHBsAg, quantitative HBsAg; RLU, relative light units

Full Text

The Full Text of this article is available as a PDF (155.8 KB).

References

  • 1.Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592. doi: 10.1016/S0140-6736(09)60207-5. [DOI] [PubMed] [Google Scholar]
  • 2.Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. doi: 10.1056/NEJM199712113372406. [DOI] [PubMed] [Google Scholar]
  • 3.Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepatol. 2004;11:97–107. doi: 10.1046/j.1365-2893.2003.00487.x. [DOI] [PubMed] [Google Scholar]
  • 4.Blumberg BS, Alter HJ, Visnich S. A “New” antigen in leukemia sera. JAMA. 1965;191:541–546. doi: 10.1001/jama.1965.03080070025007. [DOI] [PubMed] [Google Scholar]
  • 5.Werle-Lapostolle B, Bowden S, Lacorini S. Persistence of cccDNA during natural history of chronic hepatitis B and decline during adefovirdipivoxil therapy. Gastroenterology. 2004;126:1750–1758. doi: 10.1053/j.gastro.2004.03.018. [DOI] [PubMed] [Google Scholar]
  • 6.Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15:133–143. doi: 10.3851/IMP1497. [DOI] [PubMed] [Google Scholar]
  • 7.Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010;52:475–477. doi: 10.1016/j.jhep.2009.12.020. [DOI] [PubMed] [Google Scholar]
  • 8.Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA. 1991;88:1059–1063. doi: 10.1073/pnas.88.3.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schaller H, Fischer M. Transcriptional control of hepadnavirus gene expression. Curr Top Microbiol Immunol. 1991;168:21–39. doi: 10.1007/978-3-642-76015-0_2. [DOI] [PubMed] [Google Scholar]
  • 10.Vanlandschoot P, Leroux-Roels G. Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus? Trend Immunol. 2003;24:144–147. doi: 10.1016/s1471-4906(03)00026-7. [DOI] [PubMed] [Google Scholar]
  • 11.Dienes HP, Gerlich WH, Worsdorfer M. Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non-viremic chronic hepatitis B. Gastroenterology. 1990;98:1017–1023. doi: 10.1016/0016-5085(90)90028-y. [DOI] [PubMed] [Google Scholar]
  • 12.Kimbi GC, Kramvis A, Kew MC. Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B. World J Gastroenterol. 2005;11:6416–6421. doi: 10.3748/wjg.v11.i41.6416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Whitehead TP, Thorpe GHG, Carter TJN. Enhanced luminescence procedure for sensitive determination of peroxidase-labelled conjugates in immunoassay. Nature. 1983;305:158–159. [Google Scholar]
  • 14.Zacher BJ, Moriconi F, Bowden S. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol. 2011;18:1943–1950. doi: 10.1128/CVI.05122-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Deguchi M, Yamashita N, Kagita M. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Method. 2004;115:217–222. doi: 10.1016/j.jviromet.2003.10.002. [DOI] [PubMed] [Google Scholar]
  • 16.Nguyen T, Thompson AJV, Bowden S. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Gastroenterol Hepatol. 2010;52:508–513. doi: 10.1016/j.jhep.2010.01.007. [DOI] [PubMed] [Google Scholar]
  • 17.Jaroszewivz J, Serrano BC, Wursthorn K. HBsAg levels in the naturalhistory of hepatitis B virus infection: a European perspective. J Gastroenterol Hepatol. 2010;52:514–522. doi: 10.1016/j.jhep.2010.01.014. [DOI] [PubMed] [Google Scholar]
  • 18.Brunetto MR, Oliveri F, Colombatto P. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–490. doi: 10.1053/j.gastro.2010.04.052. [DOI] [PubMed] [Google Scholar]
  • 19.Martinot-Peignoux M, Lada O, Cardoso AC. Quantitative HBsAg: a new specific marker for diagnosis of HBsAg inactive carriage (Abstract) Hepatology. 2010;52:992A. [Google Scholar]
  • 20.Chen CH, Lee CM, Wang JH. Correlation of quantitative assay of HBsAg and HBV-DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol. 2004;16:1213–1218. doi: 10.1097/00042737-200411000-00021. [DOI] [PubMed] [Google Scholar]
  • 21.Manesis EK, Papatheodoridis GV, Hadziyannis E. Significance of serum HBsAg levels for the definition of the inactive HBsAg carrier state (Abstract) Hepatology. 2010;52(Suppl):560A. [Google Scholar]
  • 22.Janssen HL, Kerhof-Los CJ, Heijtink RA. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res. 1994;23:251–257. doi: 10.1016/0166-3542(94)90022-1. [DOI] [PubMed] [Google Scholar]
  • 23.Manesis EK, Hadziyannis ES, Angelopoulou OP, et al. Prediction of treatment related HBsAg loss in HBeAg negative chronic hepatitis B: a clue from HBsAg levels. Antivir Ther 207;12:73–82. [PubMed]
  • 24.Chan HL, Wong VW, Chim AM. Serum HBsAg quantification to predict response to pegylated interferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323–1331. doi: 10.1111/j.1365-2036.2010.04474.x. [DOI] [PubMed] [Google Scholar]
  • 25.Sonneveld MJ, Rijckborst V, Boucher CAB. Prediction of sustained viral response to Pegylated interferon Alfa-2b for HBeG positive chronic hepatitis B using on-treatment HBsAg decline. Hepatology. 2010;52:1251–1257. doi: 10.1002/hep.23844. [DOI] [PubMed] [Google Scholar]
  • 26.Brunetto MR, Moriconi F, Bonino F. Hepatitis B surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg negative chronic hepatitis B. Hepatology. 2009;49:1141–1150. doi: 10.1002/hep.22760. [DOI] [PubMed] [Google Scholar]
  • 27.Moucari R, Mackiewicz V, Lada O. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg negative patients. Hepatology. 2009;49:1151–1157. doi: 10.1002/hep.22744. [DOI] [PubMed] [Google Scholar]
  • 28.Marcellin P, Piratvisuth T, Brunetto MR. On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post treatment and subsequent HBsAg clearance in HBeAg negative hepatitis B virus infected patients treated with peginterferon alfa (40 kD) Hepatol Int. 2010;4:151–156. [Google Scholar]
  • 29.Reinjnders JGP, Rijckborst V, Sonneveld MJ. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449–454. doi: 10.1016/j.jhep.2010.07.046. [DOI] [PubMed] [Google Scholar]
  • 30.Jung YK, Kim JH, Lee YS. Change in serum hepatitis B surface antigen level and its clinical significance in treatment naïve hepatitis B e-antigen positive patients receiving entecavir. J Clin Gastroenterol. 2010;44:653–657. doi: 10.1097/MCG.0b013e3181d52946. [DOI] [PubMed] [Google Scholar]
  • 31.Heatcote EJ, Marcellin P, Buti M. Three-year efficacy and safety of tenofovirdisoproxilfumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143. doi: 10.1053/j.gastro.2010.10.011. [DOI] [PubMed] [Google Scholar]
  • 32.Gish RG, Chang TT, Lai CL. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside naïve HBeAg positive patients with chronic hepatitis B. J Viral Hepatitis. 2010;17:16–22. doi: 10.1111/j.1365-2893.2009.01146.x. [DOI] [PubMed] [Google Scholar]
  • 33.Wursthorn K, Jung M, Riva A. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen positive patients. Hepatology. 2010;52:1611–1620. doi: 10.1002/hep.23905. [DOI] [PubMed] [Google Scholar]
  • 34.Lok AS, McMohan BJ. Chronic hepatitis B, update 2009. Hepatology. 2009;50:661–662. doi: 10.1002/hep.23190. [DOI] [PubMed] [Google Scholar]
  • 35.Liaw YF, Leung N, Kao JH. Asia-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283. doi: 10.1007/s12072-008-9080-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242. doi: 10.1016/j.jhep.2008.10.001. [DOI] [PubMed] [Google Scholar]
  • 37.Liaw YF, Wursthorn K, Thongaswat S. Telbividine induced HBeAg seroconversion in chronic hepatitis B is durable during 2 years off-treatment follow-up. J Hepatol. 2010;52(Suppl 1):S391. [Google Scholar]
  • 38.Cai W, Xie Q, An B. On-treatment serum HBsAg level is predictive of sustained off-treatment virological response to telbividine in HBeAg positive chronic hepatitis B patients. J Clin Virol. 2010;48:22–26. doi: 10.1016/j.jcv.2010.02.014. [DOI] [PubMed] [Google Scholar]
  • 39.Yu ML, Lee CM, Chuang WL. HBsAg profiles in patients receiving pegylated interferon plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis. 2010;202:86–92. doi: 10.1086/653209. [DOI] [PubMed] [Google Scholar]
  • 40.Chan HLK, Thompson A, Martinot-Peignoux M. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol. 2011;55:1121–1131. doi: 10.1016/j.jhep.2011.06.006. [DOI] [PubMed] [Google Scholar]
  • 41.Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int. 2011;31(Suppl 1):122–128. doi: 10.1111/j.1478-3231.2010.02390.x. [DOI] [PubMed] [Google Scholar]
  • 42.Liaw YF. Clinical utility of hepatitis B surface antigen quantification in patients with chronic hepatitis B: a review. Hepatology. 2011;53:2121–2129. doi: 10.1002/hep.24364. [DOI] [PubMed] [Google Scholar]
  • 43.Sonneveld MJ, Zoutendijk R, Janssen HLA. J Viral Hepatitis. 2011;18:449–537. doi: 10.1111/j.1365-2893.2011.01465.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES